Patent · US Active

Inhibitors of receptor interacting protein kinase I for the treatment of disease

US11753381B2 · kind B2 · utility

1Cited by
1References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 25, 2020
Grant dateSep 12, 2023
Priority date—
Expiry dateNov 1, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.